On October 15, 2026, a clinical trial listing was updated to show recruiting status for a study involving bradykinin. The trial, registered as NCT07713615, is titled "Blood Clotting Markers and Heart Ultrasound in People With Device-Detected Atrial Fibrillation." No phase was specified in the listing. The study status is recorded as recruiting as of the listed date. Bradykinin remains classified as an unapproved compound under research use only. No efficacy, safety, or outcome data have been reported for this trial at this stage. The listing does not include results, dosing information, or interim findings. This update reflects only the recruitment status and title as registered on ClinicalTrials.gov under the identifier NCT07713615. Readers interested in background on this compound can consult the bradykinin overview for further context.
Bradykinin-Related Trial NCT07713615 on AFib Markers Now Recruiting
See the full bradykinin overview
Source: https://clinicaltrials.gov/study/NCT07713615